Stem cell

Global Cord Blood Banking Services Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022

Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.

Key Points: 
  • Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.
  • Key Questions Answered in This Report:
    How has the global cord blood banking services market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global cord blood banking services market?
  • What is the structure of the global cord blood banking services market and who are the key players?

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers

Retrieved on: 
Thursday, October 13, 2022

No safety-related issues or dose limiting toxicity have been reported in the first patient enrolled in the trial to date.

Key Points: 
  • No safety-related issues or dose limiting toxicity have been reported in the first patient enrolled in the trial to date.
  • The leading hospital and university centre (CHU) in Europe, Greater Paris University Hospitals and its 38 hospitals are organised into six hospital-university groups (AP-HP.
  • In 2015, Greater Paris University Hospitals also founded the Greater Paris University Hospitals Research Foundation to support the biomedical and health research performed in all its hospitals.
  • Smart Immunes partners include Memorial Sloan Kettering in New York and Greater Paris University Hospitals (AP-HP).

Penn Dental Medicine Study Identifies Possible Target to Counter Bone Loss

Retrieved on: 
Wednesday, October 12, 2022

Diseases such as osteoporosis, arthritis, and periodontitis involve bone loss, and are linked with an overabundance of osteoclast activity.

Key Points: 
  • Diseases such as osteoporosis, arthritis, and periodontitis involve bone loss, and are linked with an overabundance of osteoclast activity.
  • The work identifies the protein IFT80 as a key player in keeping populations of osteoclasts in check.
  • Yang became interested in studying the role of IFT80 in hematopoietic stem cell lineage after an earlier study in Nature Cell Biology .
  • "With so many diseases related to excess bone loss, there is a big need to find ways to address bone loss and restore balance in bone remodeling," adds Yang.

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, October 12, 2022

CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO).

Key Points: 
  • CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO).
  • Eyal also brings a demonstrated ability to execute clinical trials from start to finish in a collaborative team environment.
  • In connection with this appointment, Vor Bio granted Dr. Attar an inducement equity award in accordance with NASDAQ Listing Rule 5635(c)(4).
  • The grant, which is outside the Vor Bio 2021 Equity Incentive Plan, was approved by the Compensation Committee of the Companys Board of Directors, as an inducement material to Dr. Attar entering into employment with Vor Bio.

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy

Retrieved on: 
Wednesday, October 12, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220929006030/en/
    Under the LOI, Cellusion and Minaris will develop the manufacturing process of Cellusions leading program, CLS001, a novel regenerative medicine product for bullous keratopathy treatment.
  • We hope to position Cellusion well for its next clinical trial and potentially further support them in their manufacturing needs.
  • Cellusion is developing CLS001, CECSi cells for Corneal Endothelial regeneration to cure Bullous Keratopathy which is applied to more than half of all cases of corneal transplantation.
  • Minaris is a global CDMO for cell and gene therapies as a member of Showa Denko Materials group.

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Retrieved on: 
Tuesday, October 11, 2022

Arianna Moiani, Ph.D., Senior Scientist & Team Leader Innovation Gene Therapy, will give an oral presentation on encouraging pre-clinical data that leverages TALEN gene editing technology to develop a hematopoietic stem and progenitor cell (HSPCs)-based gene therapy to treat sickle cell disease.

Key Points: 
  • Arianna Moiani, Ph.D., Senior Scientist & Team Leader Innovation Gene Therapy, will give an oral presentation on encouraging pre-clinical data that leverages TALEN gene editing technology to develop a hematopoietic stem and progenitor cell (HSPCs)-based gene therapy to treat sickle cell disease.
  • The pre-clinical data presented at ESGCT further demonstrate our ability to leverage TALEN gene editing technology to potentially address genetic diseases, namely, sickle cell disease and lysosomal storage diseases.
  • These new milestones bring us one step closer to our goal: providing a cure to patients that have failed to respond to standard therapy.
  • Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Retrieved on: 
Tuesday, October 11, 2022

CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced data demonstrating the potential of the Company’s novel platform to use various base editing strategies to successfully delete multiple cell surface targets from hematopoietic stem cells (HSCs), potentially enabling next-generation transplants for the treatment of acute myeloid leukemia (AML). The Company is presenting the data at the European Society of Gene & Cell Therapy (ESGCT) Annual Congress in Edinburgh, UK in two separate poster presentations.

Key Points: 
  • These data show that we can potentially address this challenge by using our platform to efficiently remove one or multiple target antigens from HSCs.
  • This approach to transplant, coupled with targeted therapies, may enable the delivery of more efficacious, safer and durable treatments for patients with blood cancers.
  • Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.
  • Forward-looking statements in this press release include Vor Bios statements regarding the potential of Vor Bios multiplex editing approach for the treatment of AML and of Vor Bios approach to editing HSCs more generally, the potential efficacy, safety and durability of those treatments, the progress of Vor Bios ongoing clinical trials, and the potential of Vor Bios novel platform.

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

Retrieved on: 
Tuesday, October 11, 2022

In collaboration with Professor Axel Schambach, Ph.D., Institute of Experimental Hematology, Hannover Medical School, Germany, AVROBIO is pioneering the use of two advanced preclinical cell-based assays -- in vitro immortalization (IVIM) assay and the novel surrogate assay for genotoxicity assessment (SAGA) -- to evaluate viral vectors before they move into clinical programs. Together these assays are designed to assess which vectors are less likely to exhibit genotoxic behavior and monitor if these vectors activate proto-oncogenes (genes that may lead to cancer).

Key Points: 
  • These assays enable preclinical risk assessment of gene therapy vectors, potentially paving the way for safer gene therapy vectors used in clinical trials.
  • Combining these assays helps assess vector genotoxicity risk early in preclinical development and further reaffirms that not all lentiviral vectors are designed the same.
  • In its research, AVROBIO used the two assays in combination to determine the potential genotoxicity risk of six lentiviral vectors.
  • Machine learning algorithms developed from transcriptional data of known genotoxic vectors are used to estimate the transformational potential of candidate vectors.

Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 10, 2022

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets.

Key Points: 
  • Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets.
  • The global cell therapy market is segmented based on Use-type, Therapy Type, Product, Technology, Application, and Region.
  • Based on Technology it is categorized into Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, and Three-Dimensional Technology.
  • In November 2019, the Australian government released The Stem Cell Therapies Mission, a 10-year strategy for stem cell research in Australia.

Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas

Retrieved on: 
Monday, October 10, 2022

BOSTON and LONDON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced multiple presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh.

Key Points: 
  • BOSTON and LONDON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced multiple presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh.
  • Together with our clinical and research partners, were proud of our presence at the upcoming ESGCT Annual Congress, said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics.
  • Alongside our extensive body of clinical data and real-world evidence in MLD, our programs are showing the transformative potential of HSC gene therapy across many different genetic diseases with high unmet medical need.
  • The presentations are listed below, and the full program is available online on the ESGCT website .